A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH
Study sponsor: Spruce Biosciences
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-01-31Actual
Enrollment · participants67Actual
Source updated2025-12-24Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.